Janus Henderson Group PLC Kymera Therapeutics, Inc. Transaction History

Janus Henderson Group PLC

$187 Billion
Q3 2024

A detailed history of Janus Henderson Group PLC transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 15,108 shares of KYMR stock, worth $679,557. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,108

Previous 18,808 19.67%

Holding current value

$679,557

Previous $561,000 27.45%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$30.16 - $52.4 $111,592 - $193,880	-3,700 Reduced 19.67%	15,108 $715,000
Q2 2024 Aug 14, 2024	SELL	$29.85 - $39.42 $7,969 - $10,525	-267 Reduced 1.4%	18,808 $561,000
Q1 2024 May 15, 2024	BUY	$22.9 - $43.57 $435 - $827	19 Added 0.1%	19,075 $766,000
Q4 2023 Feb 14, 2024	SELL	$10.97 - $26.84 $383 - $939	-35 Reduced 0.18%	19,056 $485,000
Q3 2023 Nov 14, 2023	BUY	$13.9 - $23.88 $291 - $501	21 Added 0.11%	19,091 $265,000
Q2 2023 Aug 14, 2023	BUY	$22.4 - $34.92 $268 - $419	12 Added 0.06%	19,070 $438,000
Q1 2023 May 15, 2023	BUY	$24.84 - $38.75 $473,400 - $738,497	19,058 New	19,058 $564,000
Q2 2022 Aug 15, 2022	SELL	$14.13 - $42.55 $78,958 - $237,769	-5,588 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$35.3 - $64.68 $141 - $258	4 Added 0.07%	5,588 $236,000
Q4 2021 Feb 14, 2022	BUY	$49.91 - $65.56 $278,697 - $366,087	5,584 New	5,584 $355,000
Q2 2021 Aug 16, 2021	SELL	$31.08 - $51.95 $12.4 Million - $20.7 Million	-397,708 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$35.64 - $85.46 $14.2 Million - $34 Million	397,708 New	397,708 $15.5 Million

Others Institutions Holding KYMR

# of Institutions

184

Shares Held

64.4M

Call Options Held

50.6K

Put Options Held

81.7K

View Full List

About Kymera Therapeutics, Inc.

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.46B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

More about KYMR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Account

Janus Henderson Group PLC Kymera Therapeutics, Inc. Transaction History